Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Azapride

From Wikipedia, the free encyclopedia
Azapride
Clinical data
Other namesAzidoclebopride
ATC code
  • None
Identifiers
  • 4-Azido-5-chloro-2-methoxy-N-[1-(phenylmethyl)piperidin-4-yl]benzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22ClN5O2
Molar mass399.88 g·mol−1
3D model (JSmol)
  • Clc1cc(c(OC)cc1/N=[N+]=[N-])C(=O)NC3CCN(Cc2ccccc2)CC3
  • InChI=1S/C20H22ClN5O2/c1-28-19-12-18(24-25-22)17(21)11-16(19)20(27)23-15-7-9-26(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13H2,1H3,(H,23,27) checkY
  • Key:CKKHIIXHAWWTNP-UHFFFAOYSA-N checkY
  (verify)

Azapride is the azide derivative of the dopamine antagonist clebopride synthesized in order to label dopamine receptors.[1][2] It is an irreversible dopamine antagonist.[2]

References

[edit]
  1. Niznik HB, Guan JH, Neumeyer JL, Seeman P (February 1985). "A photoaffinity ligand for dopamine D2 receptors: azidoclebopride". Molecular Pharmacology. 27 (2): 193–9. doi:10.1016/S0026-895X(25)12275-X. PMID 3969068.
  2. 1 2 Wouters W, Van Dun J, Laduron PM (December 1984). "Photoaffinity labelling of dopamine receptors. Synthesis and binding characteristics of azapride". European Journal of Biochemistry. 145 (2): 273–8. doi:10.1111/j.1432-1033.1984.tb08548.x. PMID 6548707.